Zobrazeno 1 - 9
of 9
pro vyhledávání: '"István Kacsir"'
Autor:
István Kacsir, Adrienn Sipos, Tímea Kiss, Evelin Major, Nikolett Bajusz, Emese Tóth, Péter Buglyó, László Somsák, Gábor Kardos, Péter Bai, Éva Bokor
Publikováno v:
Frontiers in Chemistry, Vol 11 (2023)
The toxicity of and resistance to platinum complexes as cisplatin, oxaliplatin or carboplatin calls for the replacement of these therapeutic agents in clinical settings. We have previously identified a set of half sandwich-type osmium, ruthenium and
Externí odkaz:
https://doaj.org/article/a097cc70cbab47e5ba06c9f405874d2d
Autor:
István Kacsir, Adrienn Sipos, Evelin Major, Nikolett Bajusz, Attila Bényei, Péter Buglyó, László Somsák, Gábor Kardos, Péter Bai, Éva Bokor
Publikováno v:
Molecules, Vol 28, Iss 7, p 3058 (2023)
While platinum-based compounds such as cisplatin form the backbone of chemotherapy, the use of these compounds is limited by resistance and toxicity, driving the development of novel complexes with cytostatic properties. In this study, we synthesized
Externí odkaz:
https://doaj.org/article/30af28179b93455b82bd4840db51a689
Autor:
Bence Balázs, Zoltán Tóth, István Kacsir, Adrienn Sipos, Péter Buglyó, László Somsák, Éva Bokor, Gábor Kardos, Péter Bai
Publikováno v:
Frontiers in Chemistry, Vol 10 (2022)
Bacterial resistance to antibiotics is an ever-growing problem in heathcare. We have previously identified a set of osmium(II), ruthenium(II), iridium(III) and rhodium(III) half-sandwich type complexes with bidentate monosaccharide ligands possessing
Externí odkaz:
https://doaj.org/article/a2acd9585db44ca6a45330e393caa0c9
Autor:
István Kacsir, Adrienn Sipos, Attila Bényei, Eszter Janka, Péter Buglyó, László Somsák, Péter Bai, Éva Bokor
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 2, p 813 (2022)
Platinum complexes are used in chemotherapy, primarily as antineoplastic agents. In this study, we assessed the cytotoxic and cytostatic properties of a set of osmium(II), ruthenium(II), iridium(III) and rhodium(III) half-sandwich-type complexes with
Externí odkaz:
https://doaj.org/article/9de16b1212484091b1e5dcdecdb9d4f2
Autor:
István Kacsir, Adrienn Sipos, Gyula Ujlaki, Péter Buglyó, László Somsák, Péter Bai, Éva Bokor
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 19, p 10454 (2021)
Ruthenium complexes are developed as substitutes for platinum complexes to be used in the chemotherapy of hematological and gynecological malignancies, such as ovarian cancer. We synthesized and screened 14 ruthenium half-sandwich complexes with bide
Externí odkaz:
https://doaj.org/article/e2f21a8390e0411398a19a51e8efd3bb
Autor:
Bokor, István Kacsir, Adrienn Sipos, Attila Bényei, Eszter Janka, Péter Buglyó, László Somsák, Péter Bai, Éva
Publikováno v:
International Journal of Molecular Sciences; Volume 23; Issue 2; Pages: 813
Platinum complexes are used in chemotherapy, primarily as antineoplastic agents. In this study, we assessed the cytotoxic and cytostatic properties of a set of osmium(II), ruthenium(II), iridium(III) and rhodium(III) half-sandwich-type complexes with
Publikováno v:
Journal of inorganic biochemistry. 220
Fourteen novel CoIII ternary complexes with the general formula [Co(4 N)(2O)]X2 or [Co(2 N)2(2O)]X2 where 4 N = tris(2-aminoethyl)amine (tren) or tris(2-pyridylmethyl)amine (tpa); 2 N = 1,10-phenantroline (phen), 2,2′-bipyridine (bipy), 1,2-diamino
Autor:
Imre Zs.-Nagy, Etelka Farkas, Éva Kováts, István Kacsir, Máté Kozsup, Attila Bényei, Sándor Nagy, Péter Buglyó
Publikováno v:
Inorganica Chimica Acta. 472:234-242
Sixteen cobalt(III) complexes incorporating one of the investigated 4N donor tripodal amines in the presence or absence of differently substituted hydroxamates have been synthesized and the effect of the nature of the N-donor, size of the chelates fo
Publikováno v:
Inorganica Chimica Acta (Testo stamp.) 472 (2018): 127–138. doi:10.1016/j.ica.2017.07.064
info:cnr-pdr/source/autori:Sanna D.; Ugone V.; Buglyo P.; Nagy S.; Kacsir I.; Garribba E./titolo:Speciation in aqueous solution and interaction with low and high molecular mass blood bioligands of [VIVO(oda)(H2O)2], a V compound with in vitro anticancer activity/doi:10.1016%2Fj.ica.2017.07.064/rivista:Inorganica Chimica Acta (Testo stamp.)/anno:2018/pagina_da:127/pagina_a:138/intervallo_pagine:127–138/volume:472
info:cnr-pdr/source/autori:Sanna D.; Ugone V.; Buglyo P.; Nagy S.; Kacsir I.; Garribba E./titolo:Speciation in aqueous solution and interaction with low and high molecular mass blood bioligands of [VIVO(oda)(H2O)2], a V compound with in vitro anticancer activity/doi:10.1016%2Fj.ica.2017.07.064/rivista:Inorganica Chimica Acta (Testo stamp.)/anno:2018/pagina_da:127/pagina_a:138/intervallo_pagine:127–138/volume:472
In this work the speciation in aqueous solution of the compound [V IV O(oda)(H 2 O) 2 ], where oda is oxydiacetate dianion (OOCCH 2 ) 2 O, which shows in vitro anticancer activity, was studied. Its interaction with the two serum bioligands with highe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae9d91730f5485936a7dbaa7bf0bd709
https://www.sciencedirect.com/science/article/pii/S0020169317306242
https://www.sciencedirect.com/science/article/pii/S0020169317306242